DR. TIMOTHY EDWARD KUBAL MD
Prescription History 1982808689
Internal Medicine - Hematology & Oncology in Tampa, FL


Quality Rating: 89.43 out of 100 score

NPI Status: Active since June 14, 2007

Contact Information

12902 USF MAGNOLIA DR
TAMPA, FL
ZIP 33612
Phone: (813) 745-4673
Fax: (813) 449-6951

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. TIMOTHY EDWARD KUBAL MD, an active Hematology & Oncology specialist practicing in Tampa, FL. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 203 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydroxyurea, which accounts for 39 claims alone.


Alprazolam

Generic Formulation: AlprazolamSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.8
Days Supply 584
FL State Average Benchmarks
Peer Average Claims101.0
Peer Average 30-Day Fills112.2
Peer Average Days Supply3,201
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 78.2% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $140.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.40

State Avg Cost Per Claim

$8.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)

Therapeutic Applications

Alprazolam is used to treat anxiety and panic disorders. It belongs to a class of medications called benzodiazepines which act on the brain and nerves (central nervous system) to produce a calming effect. It works by enhancing the effects of a certain natural chemical in the body (GABA).

Deferasirox

Generic Formulation: DeferasiroxSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
FL State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.5
Peer Average Days Supply579
Conservative Utilization

This provider writes prescriptions for this formulation 36.8% less frequently than the standard regional baseline metric for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $31,833.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,652.80

State Avg Cost Per Claim

$3,125.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.

Therapeutic Applications

This medication is used to treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions (non-transfusion-dependent thalassemia). It works by binding to iron, allowing the body to pass extra iron out in the stool. Deferasirox belongs to a class of drugs known as iron-chelating agents. Frequent blood transfusions are often needed in certain types of blood diseases (such as sickle cell disease, anemia). Blood transfusions have very helpful benefits, but they can cause the body to hold on to too much iron. The extra iron can build up in the body and cause problems such as heart failure, liver disease, and diabetes. Getting rid of extra iron can decrease the risk of these diseases.

Empaveli

Generic Formulation: PegcetacoplanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
FL State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.5
Peer Average Days Supply380
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $465,933.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$38,827.82

State Avg Cost Per Claim

$38,968.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pegcetacoplan is used to treat a certain blood disorder (paroxysmal nocturnal hemoglobinuria). This disorder causes your body's immune system to destroy red blood cells, which results in anemia. It works by helping block your body's destruction of red blood cells. This effect helps lessen symptoms of anemia (such as tiredness, shortness of breath), and may reduce the need for blood transfusions.

Escitalopram Oxalate

Generic Formulation: Escitalopram OxalateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 28.0
Days Supply 840
FL State Average Benchmarks
Peer Average Claims63.0
Peer Average 30-Day Fills125.4
Peer Average Days Supply3,726
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.0% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $220.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.35

State Avg Cost Per Claim

$14.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

S-enantiomer of CITALOPRAM. Belongs to a class of drugs known as SELECTIVE SEROTONIN REUPTAKE INHIBITORS, used to treat depression and generalized anxiety disorder.

Therapeutic Applications

Escitalopram is used to treat depression and anxiety. It works by helping to restore the balance of a certain natural substance (serotonin) in the brain. Escitalopram belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRI). It may improve your energy level and feelings of well-being and decrease nervousness.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 39
30-Day Fills 76.2
Days Supply 2,251
FL State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills65.6
Peer Average Days Supply1,944
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,313.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.68

State Avg Cost Per Claim

$39.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Inqovi

Generic Formulation: Decitabine/CedazuridineSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 308
FL State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills15.1
Peer Average Days Supply417
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $95,616.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,692.42

State Avg Cost Per Claim

$8,613.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 ingredients: decitabine and cedazuridine. It is used to treat a group of blood/bone marrow disorders (myelodysplastic syndromes-MDS) in which the bone marrow does not produce enough healthy blood cells. People with MDS may have problems such as infections, anemia, and easy bleeding/bruising. Decitabine is thought to work by helping your bone marrow make normal blood cells. Decitabine also slows or stops the growth of abnormal blood cells that grow too fast and do not work properly. Cedazuridine helps decitabine work better by helping to prevent its breakdown in your body.

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 990
FL State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.9
Peer Average Days Supply743
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 37.5% more claims than the standard regional baseline profile for FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $599,272.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,159.79

State Avg Cost Per Claim

$16,454.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 667
FL State Average Benchmarks
Peer Average Claims97.0
Peer Average 30-Day Fills97.4
Peer Average Days Supply2,301
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.3% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $768.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.42

State Avg Cost Per Claim

$31.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.2
Days Supply 346
FL State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills64.3
Peer Average Days Supply1,197
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.5% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $217.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.09

State Avg Cost Per Claim

$6.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 37.0
Days Supply 1,110
FL State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills82.4
Peer Average Days Supply2,380
Conservative Utilization

This provider writes prescriptions for this formulation 41.3% less frequently than the standard regional baseline metric for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,244.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$786.84

State Avg Cost Per Claim

$917.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. TIMOTHY EDWARD KUBAL MD provides transparency into local medical care patterns within Tampa, FL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.